Sanara MedTech, Inc.

How big is Sanara MedTech, Inc.?

As of Jun 18, Sanara MedTech, Inc. has a market capitalization of 247.26 million and reported net sales of 91.57 million with a net profit of -11.64 million over the last four quarters. Shareholder's funds are 39.40 million, and total assets are valued at 88.09 million.

As of Jun 18, Sanara MedTech, Inc. has a market capitalization of 247.26 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 91.57 million, while the sum of net profit for the same period is -11.64 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 39.40 million, and the total assets are valued at 88.09 million.

What does Sanara MedTech, Inc. do?

Sanara MedTech, Inc. distributes collagen-based wound care products and operates in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $23 million and a net loss of $4 million, with a market cap of $247.26 million.

Overview:<BR>Sanara MedTech, Inc. distributes collagen-based wound care products to healthcare providers and operates within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 23 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 247.26 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.63<BR>- Return on Equity: -36.01%<BR>- Price to Book: 6.74<BR><BR>Contact Details:<BR>- Address: 1200 Summit Ave Ste 414, FORT WORTH TX: 76102-4407<BR>- Tel: 1 817 5292300<BR>- Website: https://sanaramedtech.com/

Should I buy, sell or hold Sanara MedTech, Inc.?

Who are in the management team of Sanara MedTech, Inc.?

As of March 2022, the management team of Sanara MedTech, Inc. includes Executive Chairman Ronald Nixon, Principal Executive Officer J Carmena, and Directors Robert DeSutter, Sara Ortwein, Ann Salamone, and Kenneth Thorpe. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Sanara MedTech, Inc. includes the following individuals:<BR><BR>- Mr. Ronald Nixon, who serves as the Executive Chairman of the Board.<BR>- Mr. J Carmena, who is the Principal Executive Officer and a Director.<BR>- Mr. Robert DeSutter, who is a Director.<BR>- Ms. Sara Ortwein, who is also a Director.<BR>- Ms. Ann Salamone, who holds the position of Director.<BR>- Dr. Kenneth Thorpe, who is a Director as well.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Sanara MedTech, Inc. overvalued or undervalued?

As of February 11, 2019, Sanara MedTech, Inc. is considered overvalued with a high Price to Book Value of 7.15, negative EV to EBIT and EV to EBITDA ratios, and poor returns on capital and equity, indicating a risky investment compared to its peers.

As of 11 February 2019, the valuation grade for Sanara MedTech, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued given its high Price to Book Value of 7.15 and negative EV to EBIT and EV to EBITDA ratios of -32.29 and -73.36, respectively. Additionally, the Return on Capital Employed (ROCE) stands at -14.81%, and the Return on Equity (ROE) is at -36.01%, further supporting the notion of overvaluation.<BR><BR>In comparison to its peers, CareDx, Inc. has a P/E ratio of -27.90 and EV to EBITDA of -27.82, while AngioDynamics, Inc. shows a P/E ratio of -24.69 and an EV to EBITDA of 226.06, both indicating a challenging environment for Sanara MedTech. The company's stock performance relative to the S&P 500 is not available, but the overall financial metrics suggest a concerning outlook for investors.

Is Sanara MedTech, Inc. technically bullish or bearish?

As of September 11, 2025, Sanara MedTech, Inc. shows a neutral trend with mixed signals, as the weekly MACD is bullish while the monthly MACD is bearish, and the stock has underperformed the S&P 500 across all time frames.

As of 11 September 2025, the technical trend for Sanara MedTech, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is bullish, while the monthly MACD is bearish. Bollinger Bands indicate bullishness on both weekly and monthly time frames. Moving averages show a mildly bearish trend on the daily chart. The KST is mildly bullish on both weekly and monthly charts, while Dow Theory shows a mildly bullish stance monthly but no trend weekly. The OBV is bearish monthly and shows no trend weekly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the 1-week, YTD, 1-year, 3-year, and 5-year periods, with returns of -1.81%, 4.34%, 11.35%, 11.74%, and 25.96% respectively, compared to the S&P 500's returns of 1.05%, 12.22%, 17.14%, 70.41%, and 96.61%.